SCHEMBL17699705

SCHEMBL17699705

C=CC(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
BTK Q06187 20/20 1.00
TEC P42680 2/20 0.65
TXK P42681 2/20 0.65
BMX P51813 2/20 0.65
JAK3 P52333 2/20 0.65
ITK Q08881 2/20 0.65
ERBB4 Q15303 2/20 0.65
JAK2 O60674 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17699978 0.91 BTK (1.00) BTKTECTXKBMXJAK3
SCHEMBL17699750 0.84 BTK (1.00) BTKTECTXKBMXJAK3
SCHEMBL17699743 0.82 BTK (1.00) BTKTECTXKBMXJAK3
SCHEMBL16337607 0.81 BTK (1.00) BTK
SCHEMBL17699751 0.79 BTK (0.66) BTKTECTXKBMXJAK3
SCHEMBL19715433 0.79 BTK (1.00) BTKTECTXKBMXJAK3
SCHEMBL19715353 0.79 BTK (1.00) BTKTECTXKBMXJAK3
SCHEMBL17699673 0.79 BTK (1.00) BTKTECTXKBMXJAK3
SCHEMBL29782413 0.79 BTK (1.00) BTKTECTXKBMXJAK3
SCHEMBL19715295 0.78 BTK (1.00) BTKTECTXKBMXJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170260160-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-09-14 US claimed
EP-3209656-A1 INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2017-08-30 EP claimed
US-20160115126-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2016-04-28 US claimed
US-20230192645-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2023-06-22 US disclosed
US-20230192645-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2023-06-22 US disclosed
US-11623921-B2 Indole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2023-04-11 US disclosed
US-20210107891-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-04-15 US disclosed
US-20210107891-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-04-15 US disclosed
US-20200165222-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-05-28 US disclosed
US-20200165222-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-05-28 US disclosed
US-10604504-B2 Indole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2020-03-31 US disclosed
US-20170260160-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-09-14 US disclosed
US-20170260160-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-09-14 US disclosed
EP-3209656-A1 INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2017-08-30 EP disclosed
US-9688629-B2 Indole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2017-06-27 US disclosed
US-9688629-B2 Indole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2017-06-27 US disclosed
US-20170066740-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-03-09 US disclosed
US-20170066740-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-03-09 US disclosed
US-20160115126-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2016-04-28 US disclosed
US-20160115126-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2016-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192645-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 BTK 1/4885TEC 99/4885TXK 221/4885
US-20170066740-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 BTK 1/4885TEC 99/4885TXK 221/4885
US-20170260160-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 BTK 1/4885TEC 99/4885TXK 221/4885
US-11623921-B2 Indole carboxamide compounds BTK, JAK2, BRD4 BTK 1/4885TEC 99/4885TXK 221/4885
US-20160115126-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 BTK 1/4885TEC 99/4885TXK 221/4885
US-20210107891-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 BTK 1/4885TEC 99/4885TXK 221/4885
US-20200165222-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 BTK 1/4885TEC 99/4885TXK 221/4885
US-10604504-B2 Indole carboxamide compounds BTK, JAK2, BRD4 BTK 1/4885TEC 99/4885TXK 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.